Orexo AB (ORX):企業の財務・戦略的SWOT分析

◆英語タイトル:Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1169
◆発行会社(調査会社):GlobalData
◆発行日:2020年3月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Orexo AB (ORX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar and Zubsolv. The company employs proprietary drug delivery technologies in the development of its products. It also carries out the industrial-scale production of pharmaceutical products. Orexo collaborates with various pharmaceutical companies to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jan 30,2020: Q4 incl full year report 2019
Dec 02,2019: Orexo appoints Dennis Urbaniak as Executive Vice President digital health
Nov 28,2019: Orexo acquires US rights to commercialise vorvida
Oct 24,2019: Orexo interim report Q3 2019
Aug 21,2019: Orexo and GAIA partner on digital therapy for opioid use disorder

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Orexo AB – Key Facts
Orexo AB – Key Employees
Orexo AB – Key Employee Biographies
Orexo AB – Major Products and Services
Orexo AB – History
Orexo AB – Company Statement
Orexo AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Orexo AB – Business Description
Product Category: Abstral
Overview
Performance
Product Category: Edluar
Overview
Performance
Product Category: OX-MPI
Overview
Performance
Product Category: Zubsolv
Overview
Performance
Geographical Segment: EU
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: US
Performance
R&D Overview
Orexo AB – SWOT Analysis
SWOT Analysis – Overview
Orexo AB – Strengths
Orexo AB – Weaknesses
Orexo AB – Opportunities
Orexo AB – Threats
Orexo AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Orexo AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 30, 2020: Q4 incl full year report 2019
Dec 02, 2019: Orexo appoints Dennis Urbaniak as Executive Vice President digital health
Nov 28, 2019: Orexo acquires US rights to commercialise vorvida
Oct 24, 2019: Orexo interim report Q3 2019
Aug 21, 2019: Orexo and GAIA partner on digital therapy for opioid use disorder
Jul 11, 2019: Orexo interim report Q2 2019
Jul 09, 2019: Orexo prepays part of the corporate bond loan
May 02, 2019: Orexo: Interim report Q1 2019
Jan 30, 2019: Orexo: Q4 incl. full year report 2018
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Orexo AB, Key Facts
Orexo AB, Key Employees
Orexo AB, Key Employee Biographies
Orexo AB, Major Products and Services
Orexo AB, History
Orexo AB, Subsidiaries
Orexo AB, Key Competitors
Orexo AB, Ratios based on current share price
Orexo AB, Annual Ratios
Orexo AB, Annual Ratios (Cont...1)
Orexo AB, Annual Ratios (Cont...2)
Orexo AB, Interim Ratios
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Orexo AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Orexo AB, Performance Chart (2015 - 2019)
Orexo AB, Ratio Charts
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Orexo AB (ORX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Matsuda Sangyo Co Ltd (7456):企業の財務・戦略的SWOT分析
    Matsuda Sangyo Co Ltd (7456) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Ecron Acunova-製薬・医療分野:企業M&A・提携分析
    Summary Ecron Acunova (EA), a subsidiary of Take Solutions Ltd. is a clinical research organization (CRO) serving big pharma companies locally. It offers clinical trial management, clinical data management services. Its services include bioavailability and bioequivalence services, Phase I to IV clin …
  • OGE Energy Corp (OGE):企業の財務・戦略的SWOT分析
    OGE Energy Corp (OGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bioplus Life Sciences Private Limited:戦略・SWOT・企業財務分析
    Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report Summary Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Mologen AG:企業のM&A・事業提携・投資動向
    Mologen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mologen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Inretail Peru Corp. (INRETC1):企業の財務・戦略的SWOT分析
    Inretail Peru Corp. (INRETC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Venus Remedies Ltd (VENUSREM)-製薬・医療分野:企業M&A・提携分析
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company manufactures complex formulations for oncology injections, neurology, antiseptic, pain management, anti infectives, oncology lyophilized, l …
  • Zynerba Pharmaceuticals Inc (ZYNE):企業の財務・戦略的SWOT分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formu …
  • Shin-Etsu Chemical Co Ltd (4063):企業の財務・戦略的SWOT分析
    Shin-Etsu Chemical Co Ltd (4063) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Staples Inc:企業の戦略的SWOT分析
    Staples Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Canadian Natural Resources, Ltd.:企業の戦略・SWOT・財務情報
    Canadian Natural Resources, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Canadian Natural Resources, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Eckoh PLC (ECK):企業の財務・戦略的SWOT分析
    Summary Eckoh PLC (Eckoh) is a technology service provider that offers secure payment products and customer service solutions. The company provides agent assisted payments, IVR payments, mobile and web payments and GPDR. Its agent assisted payments include DTMF Masking, audio tokenization, alternati …
  • OriGene Technologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and markets genome research and diagnostic products. OriGene provides products such as qPCR r …
  • The Binding Site Group Ltd:製品パイプライン分析
    Summary The Binding Site Group Ltd (Binding Site) is a clinical diagnostic tools supplier that concentrates on research, development, manufacturing and distribution of immunodiagnostic assays. The company’s product portfolio includes antibodies, antigens, bulk antisera, assays for plasma protein ana …
  • Israel Aerospace Industries Ltd:戦略・SWOT・企業財務分析
    Israel Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Israel Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Apexigen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company t hat focuses on discovery and development of antibody-based drugs for the treatment of cancer.The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell r …
  • GarrettCom, Inc.:企業の戦略的SWOT分析
    GarrettCom, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • IntegraGen SA (ALINT):企業の財務・戦略的SWOT分析
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • Lee Memorial Health System:企業の戦略的SWOT分析
    Lee Memorial Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ProSiebenSat.1 Media SE (PSM):企業の財務・戦略的SWOT分析
    ProSiebenSat.1 Media SE (PSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆